01Core principlesThe concepts and mechanisms needed to understand the subject.
Vaccination decisions in immunocompromised people involve two separate questions: can the vaccine cause harm, and is the person likely to mount useful protection? Non-live vaccines cannot reproduce in the recipient and are generally safe from vaccine-strain infection, although adverse effects and product contraindications remain. Live attenuated organisms replicate; when cellular control is markedly impaired they can cause disseminated disease. Therefore vaccine platform, immune mechanism and treatment timing must be matched explicitly.
Immune state is dynamic. Ask about diagnosis, transplant, chemotherapy, radiotherapy, biological or targeted therapy, corticosteroid exposure, splenic function, HIV status, immunoglobulin replacement and expected treatment dates. Retrieve vaccine records rather than relying on recall. Treatment names alone are insufficient: intensity, combination, duration and time since the last dose affect both safety and response. When uncertain, contact the prescribing specialist or immunisation team instead of permanently withholding protection.
Planning before immunosuppression creates opportunity. Green Book Chapter 7 generally prefers indicated inactivated vaccines at least 2 weeks before immunosuppressive treatment so an immune response can develop, while agent-specific advice can require different timing. Examples of non-live products include conjugate pneumococcal, recombinant shingles, injectable inactivated influenza and current COVID-19 vaccines; examples of live products include MMR/MMRV, varicella, intranasal live attenuated influenza and yellow fever vaccines. Verify the exact product because formulations change. Do not delay urgent disease treatment solely to complete vaccination without specialist agreement. For rheumatoid arthritis treated with MabThera, its product information specifies completion at least 4 weeks before the first infusion. Apply the national risk-group schedule separately from the drug-specific treatment interval.
Live vaccine decisions require the current Green Book Chapter 6 definition of immunosuppression and the relevant vaccine chapter. Severe T-cell impairment, many biologic or targeted treatments, high-intensity corticosteroids, chemotherapy and transplant settings can contraindicate live vaccination for specified periods. Do not invent a universal waiting interval: different agents have different pharmacology and immune effects. Maternal biological exposure can also affect infant live-vaccine timing and warrants specialist review.
Contacts are part of the protective environment. Routine vaccination of household members is generally beneficial, but check precautions for the particular live product and severely immunocompromised contact. Influenza vaccination of eligible close contacts and other programme measures can reduce exposure. Vaccination never creates perfect protection, so patients still need advice on fever, exposure and prompt assessment. Antibody testing is useful only where a validated correlate and pathway specify how the result changes action.
Exposure is an urgent clinical problem, not a future clinic task. Establish organism, contact, timing, immune state, vaccine and disease history, pregnancy and treatment. Contact infection, microbiology or health protection services promptly for post-exposure vaccination, immunoglobulin, antiviral or monitoring decisions under the specific current guidance. Document vaccine product, batch, date, route, advice, deferral reason and the named service responsible for subsequent doses.
Key points
- Do not use “immunocompromised” as one category: define disease, treatment, dose, duration, timing, transplant status, immune recovery and previous vaccine response.
- Inactivated and non-live vaccines cannot replicate and are generally safe, but immune response may be reduced and extra doses or timing changes may be recommended.
- Live attenuated vaccines can cause vaccine-strain disease in severe immunosuppression and are usually contraindicated unless an authoritative specialist pathway explicitly permits them.
- Review vaccination before planned immunosuppression whenever feasible; completing indicated vaccines earlier may improve response and avoid later live-vaccine constraints.
- Use the current Green Book and disease-specific chapter on the day of decision because UK schedules, products, eligibility and definitions change.
- Household and close-contact vaccination can reduce exposure, but some live vaccines require specific precautions; check the relevant Green Book chapter.
- After significant exposure to measles, varicella or another preventable infection, seek urgent specialist or health-protection advice because post-exposure options are time dependent.
02Mechanisms and patternsImportant relationships and how to distinguish them.
Severe immunosuppression can permit uncontrolled vaccine-organism replication; identify vaccine platform rather than relying on brand familiarity.
B-cell depletion, transplantation, chemotherapy and other immune defects can reduce immunogenicity even when a non-live vaccine is safe.
A planned start date permits earlier record review, indicated vaccination and specialist timing before immune suppression deepens.
Biological therapy during pregnancy or breastfeeding may affect infant live-vaccine safety depending on agent and exposure; seek specialist advice.
Close contacts can reduce risk through recommended vaccination but need product-specific advice for certain live vaccines.
Measles, varicella and other exposures may require prompt risk assessment and post-exposure action before routine appointments.
Current eligibility and formulations can change by season and year, so the live Green Book outranks a memorised schedule.
03Interpreting evidenceInformation, measurements and their limitations.
Consider the information, its meaning and its limitations before deciding what follows.
- 01
Immune-state definition - Why
- Record disease, therapy, dose, combination, last and next treatment, transplant stage and relevant immune recovery.
- Interpretation and limitations
- Map these facts to current Green Book definitions and specialist advice; a generic immunosuppressed label cannot determine safety.
- 02
Verified vaccine history - Why
- Retrieve GP, child health, occupational and specialist records and note proven disease or serology where relevant.
- Interpretation and limitations
- Construct a dated record, distinguishing documented doses from recollection, then identify routine and risk-based gaps.
- 03
Vaccine-platform check - Why
- Classify each proposed product as live attenuated or non-live using current official information.
- Interpretation and limitations
- Platform determines vaccine-strain risk; product names and formulations can change, so verify the exact item.
- 04
Timing review - Why
- Relate vaccination to planned, current and recently stopped immune-modifying treatment.
- Interpretation and limitations
- Safety and response vary by agent and recovery; use the relevant product, specialist and Green Book interval rather than a universal rule.
- 05
Exposure assessment - Why
- Define pathogen, contact intensity, date, susceptibility, immune state and pregnancy.
- Interpretation and limitations
- Urgent health-protection or specialist advice selects time-sensitive post-exposure prophylaxis and follow-up.
- 06
Response or revaccination plan - Why
- Identify whether the pathway recommends extra doses, post-vaccine serology or repeating vaccines after recovery.
- Interpretation and limitations
- Test antibodies only when a validated correlate and explicit action pathway exist; a negative result is not interpreted generically.
04Applied reasoningWorked examples connecting principles to decisions.
01Worked caseVaccination before B-cell-depleting therapyA 48-year-old with rheumatoid arthritis is due first MabThera (rituximab) in eight weeks. Specialist pre-treatment assessment has confirmed that the severe-immunosuppression pneumococcal schedule applies. Records show no previous adult pneumococcal vaccination, no active infection and no relevant vaccine allergy; the planned treatment date is clinically acceptable.+
- 1Confirm the specialist risk classification, treatment date and complete vaccination history. The severe-immunosuppression input is supplied for this case; do not assume every person with rheumatoid arthritis or every biologic prescription automatically has the same schedule.
- 2Choose PCV20, a non-live conjugate vaccine. Current UKHSA guidance requires two doses at least 4 weeks apart for this severe-immunosuppression group. MabThera product information for rheumatoid arthritis requires vaccination to be completed at least 4 weeks before the first infusion; the general 2-week preference does not replace that agent-specific interval.
- 3Through the authorised service, give PCV20 0.5 mL intramuscularly in the deltoid now, after consent and product checks, and book the second 0.5 mL dose for week 4. This leaves 4 further weeks before planned rituximab at week 8. The two-dose course follows national risk-group guidance. If dates change, obtain a specialist revised plan rather than compressing intervals or independently delaying urgent treatment.
- 4Document product, batch, date, route and administration of each dose; verify actual course completion and the final 4-week interval with the treatment team. Review other vaccine gaps separately and give an owned follow-up plan, recognising that vaccination does not guarantee adequate protection during B-cell depletion.
02Safety processLive vaccine request during immunosuppressionA patient receiving combination immunosuppressive treatment asks for a travel vaccine that may be live.+
- 1Do not administer until the exact product and current degree of immunosuppression are verified.
- 2Review the relevant Green Book and travel-health guidance and contact the prescribing specialist or expert travel service.
- 3Consider destination risk, non-live alternatives, itinerary changes or deferral through specialist shared decision making.
- 4Record the decision, rationale and contingency, and ensure the patient understands that a contraindicated live vaccine can cause disease.
03Emergency approachVaricella exposureA severely immunosuppressed person reports close household exposure to chickenpox yesterday and is unsure of past infection.+
- 1Confirm exposure timing and nature, symptoms, pregnancy where relevant, treatment and any documented vaccine, disease or antibody history.
- 2Contact the designated infection, microbiology or health-protection service urgently because eligibility and choice of prophylaxis are time dependent.
- 3Follow the current UKHSA varicella post-exposure pathway for testing and prophylaxis; do not improvise a vaccine or medicine regimen.
- 4Give symptom and access advice, document the exposure and plan, and verify that the responsible service reviewed results and delivered prophylaxis if indicated.
05Checking understandingVerify the reasoning, revisit uncertainties and apply feedback.
- Maintain a dated vaccine and treatment timeline, including product, batch, route, immune therapy and deferral rationale.
- Before each dose, recheck immune status because treatment may have started, stopped or intensified since the plan was written.
- Track multi-dose courses and revaccination to completion with a named service and recall process.
- Use post-vaccine serology only where a validated programme specifies timing and action, interpreting it with immunoglobulin therapy and B-cell function.
- Review exposure advice and ensure the patient knows which contacts require urgent same-day communication.
- Update household and close-contact recommendations when the patient’s immune status or national programme changes.
06Special situationsVariants, exceptions and circumstances that change the usual approach.
Safe does not mean effective
A non-live vaccine may be safe during therapy yet elicit a weak response; timing and later repeat doses can matter.
Contraindication is product-specific
A live vaccine hazard cannot be transferred automatically to every product for the same disease because platforms differ.
Intervals are pharmacological
Immune recovery after different therapies varies, so one memorised three-month rule is unsafe across agents and combinations.
Replacement immunoglobulin complicates evidence
Passive antibodies can alter serology and interact with some live vaccines; specialists should time testing and vaccination.
Contacts extend protection
Vaccinating close contacts often reduces exposure, while product-specific precautions prevent transmission of a live vaccine organism.
Exposure pathways change quickly
Post-exposure recommendations incorporate circulating disease, products and eligibility; consult the current UKHSA document immediately.
Deferral needs ownership
Writing “after immunosuppression” without a date, criterion and responsible service usually creates permanent omission.
07Common pitfallsFrequent interpretation and management errors.
- 01
Assuming all vaccines are contraindicated and leaving a high-risk person unprotected.
- 02
Administering a live vaccine from an old schedule without checking current immune state and product.
- 03
Using one fixed interval after every immunosuppressive medicine.
- 04
Delaying urgent disease treatment solely to complete vaccination without specialist agreement.
- 05
Ordering antibody tests that lack a validated correlate or planned action.
- 06
Treating a significant exposure as a routine appointment and missing the prophylaxis window.
- 07
Deferring a dose without a named owner, recall date and immune-recovery criterion.